Response to the EMA’s consultation on draft policy on access to clinical trial data

The European Medicines Agency (EMA) ran a consultation to discuss their proposed policy for access to clinical trial data for data submitted to the EMA from January 2014.

BPS noted support for the policy, suggested potential improvements and highlighted the wider issues regarding clinical trial data transparency which should be addressed.

• Read the Society's full response to the consultation here.